N/A N=25

AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

Atrial Fibrillation, Persistent · Atrial Fibrillation · Arrhythmias, Cardiac · Heart Diseases

Bottom Line

View on ClinicalTrials.gov: NCT05481359 ↗

Enrolled (actual)

Serious AEs

4.0%

Results posted

Apr 2025

Primary outcome: Primary: Number of Participants With Acute Procedure Success — 13 Participants

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Electrographic Flow™ (EGF) mapping and ablation (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ablacon, Inc.
Primary completion: Oct 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Acute Procedure Success	13	—
SECONDARY Number of Participants With 12-month Freedom From AF Recurrence	8; 6	—

Summary

This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.

Eligibility Criteria

Inclusion Criteria

Suitable candidate for intra-cardiac mapping and ablation of arrhythmias.
Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law.
Subjects with a history of documented symptomatic atrial fibrillation.

Exclusion Criteria

Subjects who are not candidates for cardiac ablation procedures.
Pregnant or nursing.
Presence of anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or comply with follow-up requirements.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05481359). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.